| John Rudolph Ahmann, DO | |
|
300 Locust Street, Suite 540, Akron, OH 44302-1809 | |
| (330) 543-8348 | |
| Not Available |
| Full Name | John Rudolph Ahmann |
|---|---|
| Gender | Male |
| Speciality | Pediatrics - Neonatal-perinatal Medicine |
| Location | 300 Locust Street, Akron, Ohio |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083710867 | NPI | - | NPPES |
| 2400691 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2080N0001X | Pediatrics - Neonatal-perinatal Medicine | 34008025 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| John Rudolph Ahmann, DO 300 Locust Street, Suite 540, Akron, OH 44302-1809 Ph: (330) 543-8348 | John Rudolph Ahmann, DO 300 Locust Street, Suite 540, Akron, OH 44302-1809 Ph: (330) 543-8348 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.
A study published today in the August edition of the Journal of Cataract & Refractive Surgery reports that wavefront technology, a new way of measuring how vision is distorted by irregularities in the eye, offers a widely accepted means for corroborating cataract patients' vision complaints, which may lead to earlier treatment with attendant enhanced patient safety and less loss of quality of life.
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers.
The most common connective tissue cell in animals is the fibroblast, which plays an important role in healing wounds. But Dr. Neta Erez of Tel Aviv University's Sackler Faculty of Medicine has now demonstrated that fibroblasts can also do a body great harm, helping to "recruit" immune cells for tumor growth.
Diamyd Medical AB, to date no drug related Serious Adverse Events have been reported by any patient included in Diamyd's Phase I clinical trial investigating NP2 as a potential therapy for chronic pain. Based upon the Phase I findings to date, the company is planning a multi-center, randomized, double-blind, placebo controlled Phase II clinical trial with NP2 in the United States.
› Verified 2 days ago
Katrina Regula, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 701 White Pond Dr Ste 100, Akron, OH 44320 Phone: 330-865-1252 Fax: 330-865-1260 | |
Dr. Hiba Khankan, M.D Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Perkins Sq, Akron, OH 44308 Phone: 330-543-8178 Fax: 330-543-8157 | |
Amanda Gogol-tagliaferro, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 215 W Bowery St, Akron, OH 44308 Phone: 330-543-8530 Fax: 330-543-3731 | |
Laura Discenna, Pediatrics Medicare: Medicare Enrolled Practice Location: 1463 Canton Rd, Akron, OH 44312 Phone: 330-253-4931 Fax: 330-253-8619 | |
Michael L. Bowman, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1 Perkins Sq, Akron, OH 44308 Phone: 330-543-8004 | |
Sarah E Kline Krammes, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Perkins Sq, Akron, OH 44308 Phone: 330-543-1000 | |
Vanisha Patel, Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1 Perkins Sq, Third Floor, Akron, OH 44308 Phone: 330-543-5191 |